SM
HZNP

Sabby Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Sabby Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-164,658
Closed -$3.26M – 403
2015
Q3 		$3.26M Buy
+164,658
New +$5.2M 0.13% 115

Other funds holding HZNP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Sabby Management's HZNP Position: Q4 2015 in Review

Sabby Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2015, closing a stake of 164,658 shares — an estimated $3.26M sold.

Sabby Management first reported a position in HZNP in Q3 2015 and held it in 1 quarter. The position peaked at $3.26M in Q3 2015. 202 funds tracked by Wall St. Rank hold HZNP as of Q4 2015.

  • Sabby Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2015 after selling out during the quarter.
  • Sabby Management sold 164,658 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2015, an estimated $3.26M.
  • Sabby Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2015 and held it in 1 quarter.
  • Sabby Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $3.26M in Q3 2015.
  • 202 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2015.

Based on Sabby Management's 13F filing for Q4 2015, filed 16 Feb 2016.